Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

Also Read: Dexcom’s Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients ... and does not apply to the FreeStyle Libre 3 reader or app.

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...

Abbott’s FreeStyle Libre products have more than six million users who have type 1 or type 2 diabetes. She added that the collaboration provides people with diabetes expanded choice, calling it ...

Meanwhile, Abbott's FreeStyle Libre and FreeStyle Libre 2 flash CGM systems remain available to patients and listed on the NHS Drug Tariff. The FreeStyle Libre 3 system consists of the sensor ...

Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...

Returns for ABT stock were 31% in 2021, -21% in 2022, and 2% in 2023, while for MDT stock ... seeing double-digit growth lately, led by FreeStyle Libre. The nutritional segment is benefiting ...

again accusing Abbott of patent infringement for its FreeStyle Libre 2 device. This sparked a flurry of litigation between the parties in the US. Since 2021, Abbott and DexCom have been involved ...